AR and posterior cortical atrophy: ctDNA has been used to screen for androgen receptor gene mutations in PCa patients who develop castration-resistant metastatic cancer to achieve prognostic and therapeutic goals or to determine genomic mutational burden in relation to disease aggressiveness and progression [19].